TheStreet upgraded shares of Repligen (NASDAQ:RGEN) from a c rating to a b- rating in a report published on Tuesday, March 13th.
Other research analysts have also issued research reports about the company. CL King initiated coverage on Repligen in a research report on Monday, November 13th. They set a buy rating and a $41.00 price objective for the company. BidaskClub raised shares of Repligen from a hold rating to a buy rating in a report on Saturday, December 30th. Citigroup began coverage on shares of Repligen in a report on Friday, December 8th. They issued a buy rating and a $45.00 price target for the company. Zacks Investment Research downgraded shares of Repligen from a buy rating to a hold rating in a research note on Wednesday, January 24th. Finally, JPMorgan Chase began coverage on shares of Repligen in a research note on Tuesday, December 5th. They issued an overweight rating and a $42.00 price objective for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Repligen has an average rating of Buy and a consensus price target of $44.38.
Shares of NASDAQ RGEN remained flat at $$36.47 during midday trading on Tuesday. The stock had a trading volume of 273,680 shares, compared to its average volume of 249,449. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.63 and a quick ratio of 8.08. The company has a market cap of $1,589.67, a PE ratio of 52.10, a price-to-earnings-growth ratio of 2.44 and a beta of 0.87. Repligen has a 12-month low of $29.56 and a 12-month high of $46.81.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. Repligen had a return on equity of 7.08% and a net margin of 20.08%. The firm had revenue of $41.60 million during the quarter, compared to analyst estimates of $41.13 million. During the same period in the prior year, the business posted $0.08 EPS. Repligen’s revenue was up 62.5% on a year-over-year basis. analysts expect that Repligen will post 0.7 EPS for the current fiscal year.
In other Repligen news, CEO Anthony Hunt sold 8,970 shares of Repligen stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total value of $322,471.50. Following the transaction, the chief executive officer now directly owns 83,613 shares of the company’s stock, valued at $3,005,887.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 4,696 shares of Repligen stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $36.16, for a total transaction of $169,807.36. Following the completion of the transaction, the director now directly owns 9,700 shares in the company, valued at $350,752. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.
Several large investors have recently bought and sold shares of the company. First Manhattan Co. lifted its stake in shares of Repligen by 16.7% during the fourth quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after buying an additional 1,500 shares during the period. California Public Employees Retirement System lifted its position in Repligen by 1.6% during the third quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock valued at $4,696,000 after purchasing an additional 1,948 shares during the period. Nationwide Fund Advisors lifted its position in Repligen by 2.4% during the third quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock valued at $3,237,000 after purchasing an additional 1,979 shares during the period. Cornerstone Capital Management Holdings LLC. lifted its position in Repligen by 12.3% during the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 18,206 shares of the biotechnology company’s stock valued at $660,000 after purchasing an additional 2,000 shares during the period. Finally, Swiss National Bank lifted its position in Repligen by 5.3% during the fourth quarter. Swiss National Bank now owns 63,700 shares of the biotechnology company’s stock valued at $2,311,000 after purchasing an additional 3,200 shares during the period. Institutional investors and hedge funds own 87.61% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/repligen-rgen-lifted-to-b-at-thestreet.html.
Repligen Company Profile
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.